Malignant brain tumors, either primary or secondary to systemic cancer, remain a tremendous challenge in clinical oncology because of the limited utility of currently available treatment options. The increasing frequency of neoplastic disease of the central nervous system urgently calls for novel experimental therapeutics improving the outlook for affected patients. We have developed a promising new therapeutic modality directed against malignant brain tumors based on poliovirus recombinants devoid of pathogenic properties. A candidate oncolytic poliovirus recombinant for the treatment of malignant glioma is being prepared for production for Phase-I clinical trials. Our approach is based on mechanisms of viral gene expression to direct viral replication and cell killing specifically to tumor cells. Through genetic manipulation of a poliovirus translation control element, we achieved specific targeting of tumor cells for destruction by replicating virus. We plan to conduct experiments to identify the role of eukaryotic factors associated with brain tumors and tumor specific viral cytotoxicity. Isolation of cellular factors responsible for targeting of tumor cells and the characterization of the molecular mechanism of their action will help to identify tumor types likely to respond favorably to our treatment. Furthermore, the elucidation of the mechanisms responsible for selective tumor cell killing by oncolytic polioviruses will make this principle applicable in novel ways. Recently, improved forms of delivery for macromolecules to the human brain have been developed. To optimize treatment conditions of our agent in upcoming clinical trials, we will perform comprehensive evaluation of alternative means of administration of our agent in a rat brain tumor model. In addition, we will analyze the therapeutic potential of our treatment against neoplastic meningitis, an increasingly common CNS complication of systemic cancers, in a rat tumor model. Using our insight into mechanism of tumor-specific viral replication, we will construct recombinant alpha-Herpesviruses replicating under control of poliovirus regulatory 5' non-translated sequences. We are aiming to generate a novel prototype of oncolytic virus based on highly attenuated Herpesviruses with tumor-specific replication profiles.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS020023-24
Application #
7415182
Study Section
Special Emphasis Panel (ZNS1)
Project Start
Project End
Budget Start
2007-02-01
Budget End
2008-01-31
Support Year
24
Fiscal Year
2007
Total Cost
$262,376
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Saraswathula, Anirudh; Reap, Elizabeth A; Choi, Bryan D et al. (2016) Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. Cancer Immunol Immunother 65:205-11
Slastnikova, Tatiana A; Rosenkranz, Andrey A; Zalutsky, Michael R et al. (2015) Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets. Curr Pharm Des 21:1227-38
Huang, Dong-Sheng; Wang, Zhaohui; He, Xu-Jun et al. (2015) Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer 51:969-76
Mitchell, Duane A; Batich, Kristen A; Gunn, Michael D et al. (2015) Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519:366-9
Koumarianou, Eftychia; Slastnikova, Tatiana A; Pruszynski, Marek et al. (2014) Radiolabeling and in vitro evaluation of (67)Ga-NOTA-modular nanotransporter--a potential Auger electron emitting EGFR-targeted radiotherapeutic. Nucl Med Biol 41:441-9
Choi, Bryan D; Suryadevara, Carter M; Gedeon, Patrick C et al. (2014) Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. J Clin Neurosci 21:189-90
Brown, Michael C; Dobrikova, Elena Y; Dobrikov, Mikhail I et al. (2014) Oncolytic polio virotherapy of cancer. Cancer 120:3277-86
Miao, Hongsheng; Choi, Bryan D; Suryadevara, Carter M et al. (2014) EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLoS One 9:e94281
Killela, Patrick J; Pirozzi, Christopher J; Healy, Patrick et al. (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5:1515-25
Lathia, Justin D; Li, Meizhang; Sinyuk, Maksim et al. (2014) High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. Cell Rep 6:117-29

Showing the most recent 10 out of 146 publications